[Association between serum soluble CD146 level and plaque vulnerability in carotid atherosclerosis]

To explore the relationship between circulating level of soluble CD146 (sCD146) and plaque vulnerability or inflammatory factors in patients with carotid atherosclerosis (CAS).

Forty CAS patients with carotid stenosis ( ≥ 70%) were enrolled and divided into 2 groups of stable and unstable plaque by ultrasonic imaging. And another 40 healthy subjects were enrolled for control group. Double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) was employed to measure the serum levels of sCD146 and matrix metalloproteinase-9 (MMP-9), analyze the correlation of sCD146 with MMP-9 and high sensitivity CRP (hs-CRP), and evaluate whether sCD146 correlates with plaque vulnerability.

Soluble CD146 level was elevated in CAS patients versus healthy donors [(212 ± 43) vs (173 ± 36) ng/ml, P < 0.001]. And sCD146 level significantly increased in CAS patients with unstable plaques than those with stable plaque [(218 ± 28) vs (176 ± 25) ng/ml, P < 0.001]. And sCD146 was correlated with high-sensitivity C-reactive protein (hsCRP, r = 0.370 9, P = 0.018 5), a well-known marker for CAS inflammation. Also it was an independent risk factor for plaque vulnerability (OR = 1.16, 95%CI:1.020-1.310, P = 0.019 2). And its level was not correlated with the risk factors of CAS, such as age, homocysteine, triglyceride, total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C) or high density lipoprotein-cholesterol (HDL-C) (P > 0.05). But there was a good correlation with the serum level of MMP-9 in CAS patients (r = 0.677 2, P < 0.001).

The concentration of soluble CD146 is positively correlated with hsCRP and MMP-9 in CAS patients. And inflammation and neovascularization may interact with each other during atherosclerotic process. The serum level of sCD146 is correlated independently with plaque vulnerability.